This is the best company to work for in the U.S; here are the top 10 that make up the list
A recent award ceremony which is actually significant revealed about the best companies right now existing in the country US ...
fnarena7h
ResMed: Another Positive Quarterly Surprise?
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
Are weight-loss drugs like gym memberships? The answer is worth billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
pharmaphorum18h
EMA abandons X in favour of rival Bluesky
The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...
Global Diabetic Nephropathy Market To Reach $3.3 Billion By 2031, Growing At A CAGR Of 6%
The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.
Xerox (NYSE:XRX) Upgraded by StockNews.com to Buy Rating
StockNews.com upgraded shares of Xerox (NYSE:XRX – Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning. Several other research analysts also recently commented on XRX ...
Telangana Today6h
"eli-lilly"
Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.